Shares of lab services company Charles River Laboratories (NYSE:CRL)
fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Lab services company Charles River Laboratories (NYSE:CRL)
will be announcing earnings results this Wednesday before market hours. Here’s what you need to know.
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 2.6% in the afternoon session after the stock's positive momentum continued, as Barclays upgraded the company to Overweight from Equal Weight and raised its price target.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Renowned investor Kevin O’Leary expressed his belief on Wednesday that owning only Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) can capture the majority of the cryptocurrency market’s volat
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
